asa statement on glp 1 Perioperative management of patients taking glucagon-like peptide-1 receptor agonists: a restrictive fasting regimen is not necessary. Comment Br J Anaesth 2025; 135: 48–78 Anesthetic Considerations for Patients Taking

For operators, this translates into three clear menu imperatives

Changes in body weight and self-reported depressive symptoms from baseline to 56 weeks were assessed as coprimary endpoints

Semaglutide, marketed as Ozempic, Wegovy, and Rybelsus, is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management

The inhibition of the onset and progression of DKD is an urgent issue, and the development of therapeutic approaches against DKD is required

Bariatric Surgery versus Intensive Medical Therapy for Diabetes 5-Year Outcomes

Genetics, appetite regulation, metabolism, fat storage, energy expenditure, GLP-1, GIP, leptin, ghrelin, and insulin may influence weight regulation